Introduction {#s1}
============

Weaver syndrome (MIM 277590) is one of the overgrowth syndromes, which is characterized by excessive growth either of pre- or post-natal onset, craniofacial abnormalities (macrocephaly, round face in infancy, broad forehead, flat occiput, ocular hypertelorism, long prominent philtrum, small dimpled chin, large low set ears and depressed nasal bridge), advanced and disharmonic bone age, developmental delay, metaphyseal flaring of the long bones and camptodactyly ([@r1]). Since Weaver et al reported this syndrome in 1974 ([@r2]), more than forty cases including five Japanese patients ([@r3],[@r4],[@r5]) have been reported. Most of the cases have been sporadic, and males have been affected more frequently than females ([@r1]). Since there has not been any obvious causative gene mapped or isolated so far, diagnosis of Weaver syndrome must be established by clinical features alone. However, clinical manifestations of Weaver syndrome overlap those of Sotos syndrome (MIM 117550) ([@r6], [@r7]), so that it is sometimes difficult to make a differential diagnosis. Excessive growth in childhood that is usually normalized by adulthood, characteristic face (macrodolichocephaly with frontal bossing, high hair line, long face, down-slanting palpebral fissures, ocular hypertelorism, prominent jaw and highly arched palate), advanced bone age and developmental delay are observed in Sotos syndrome ([@r8]). Recently, a mutation of the *NSD1* (MIM 606681; Genebank accession number, AF395588) gene on 5q35 has been reported to be a major cause of Sotos syndrome ([@r9]). The function of *NSD1* remains largely unknown, and the mutation of this gene has been detected in certain cases of Weaver syndrome ([@r10]), suggesting that Sotos syndrome and Weaver syndrome might be allelic. To make a differential diagnosis, comprehensive assessment of the patient is required. Herein, we reported a typical case of Weaver syndrome with examination of the *NSD1* gene.

Case Report {#s2}
===========

The patient was a 5 yr and 7 mo old Japanese female. Her parents were both healthy and unrelated. There was no family history of similarly affected individuals. Her father was 177 cm (+ 1.1 SD) tall, and her mother was 169 cm (+ 2.1 SD) tall. After an uncomplicated pregnancy, she was vaginally delivered at 38 wk of gestation with a length of 54.2 cm (+ 2.6 SD), a weight of 3805 g (+ 2.5 SD) and an OFC of 35.0 cm (+ 1.1 SD). Since no serious problems were noted except for the submucosal soft cleft palate, she was discharged at 5 d old. One week later she gradually showed dyspnea and cyanosis during sucking. She was hospitalized again for a survey of the respiratory problem at 20 d old. Similar to Pierre Robin sequence, a small mandible with glossoptosis caused cyanosis with stridor in the patient. She had a characteristic face: macrocephaly, broad forehead, ocular hypertelorism, long prominent philtrum and small dimpled chin. Large hands and feet, camptodactyly of both hands, flexion contractures of the elbows and knees, increased muscle tone and low-pitched hoarse cry were also noticed. Stridor and cyanosis gradually disappeared after tube feeding and head-up positioning started. As the oral intake increased, tube feeding was withdrawn. Accompanied by good appetite, subsequent growth accelerated and her height and weight became advanced for her age ([Fig. 1](#fig_001){ref-type="fig"}Fig. 1Growth chart.). Radiographic survey of the extremities showed widening of the distal end of the long bones. The epiphyses of femoral capitus were large and slightly mottled. Serial surveillance of bone age demonstrated acceleration for age, and carpal bone age was more advanced to phalangeal bone age. Routine laboratory examinations were unremarkable. Both serum GH and IGF-1 levels were not elevated. High-resolution chromosomal analysis on peripheral blood lymphocytes demonstrated normal female karyotype. Judging from these clinical features including overgrowth, characteristic face and advanced bone age, the patient was diagnosed as having Weaver syndrome. Hypertonia and contractures gradually resolved. Motor development was within normal range, but language acquisition was mildly delayed. She underwent surgery for submucosal soft cleft palate at 18 mo old.

As the girl's growth was continuously advanced for her age ([Fig. 1](#fig_001){ref-type="fig"}), she was re-evaluated at 5 yr and 7 mo old. Her height, weight and OFC were 133.3 cm (+ 5.5 SD), 32.0 kg (+ 5.1 SD), and 56.8 cm (+ 4.1 SD), respectively. She showed craniofacial abnormalities: macrocephaly, broad forehead, flat occiput, ocular hypertelorism, down-slanting palpebral fissures, long prominent philtrum, eversion of the lower lip with an open-mouth appearance, small dimpled chin, large low set ears and depressed nasal bridge ([Fig. 2](#fig_002){ref-type="fig"}Fig. 2Facial appearances of the patient (Permission was obtained from the parents). (a) 6 mo old, (b) 4 yr and 1 mo old, (c, d) 5 yr and 7 mo old.). Hoarse low-pitched voice, large hands and feet, and mild camptodactyly of both hands were also noticed. Breast development was in Tanner stage I. Neurological examination did not show any abnormal findings. She was shy toward strangers and tilted her head down when viewing her surroundings.

Routine serum and urinary laboratory investigations did not show any specific changes. Serum and urinary amino acid analyses were normal. Endocrinological survey to detect the cause of overgrowth revealed no obvious abnormalities: TSH 4.01 *μ*U/ml, freeT4 1.3 ng/dl, freeT3 3.1 pg/ml, FSH 1.6 mIU/ml, LH \< 0.2 mIU/ml, E2 \< 10 pg/ml, GH 3.3 ng/ml, PTH 30.0 pg/ml, ACTH 59 pg/ml, cortisol 7.8 *μ*g/dl. IGF-1 (78 ng/ml) was a little low for her age (91--344 ng/ml), whereas IGFBP-3 (2.69 *μ*g/ml) was normal for her age (1.76--4.03 *μ*g/ml). Oral glucose tolerance test showed a normal glucose/insulin pattern and suppression of GH secretion. Normal responses of GH (basal 2.4, peak 18.7 ng/ml), FSH (basal 1.6, peak 15.5 mIU/ml), LH (basal \<0.2, peak 2.4 mIU/ml), TSH (basal 4.01, peak 21.09 *μ*U/ml), and prolactin (basal 6.5, peak 30.8 ng/ml) were observed in response to appropriate stimulation of insulin-induced hypoglycemia, LH-releasing hormone and TRH. Elevated levels of osteocalcin (5.5 ng/ml), bone alkaline phosphatase (138 IU/L) and urinary deoxypyridinoline (26.6 nmol/mmol.Cre) indicated high turnover of bone metabolism. Radiographic studies showed accelerated disharmonic osseous maturation with carpal bone age of 8.6 yr and phalangeal bone age of 7.1 yr according to the Tanner-Whitehouse 2 method ([Fig. 3a](#fig_003){ref-type="fig"}Fig. 3Radiographic surveys of the left hand and femora at 5 yr and 7 mo old. (a) Accelerated disharmonic osseous maturation and short fifth metacarpal bone. (b) Splaying of the distal femora.). Splaying of the distal femora was also demonstrated ([Fig. 3b](#fig_003){ref-type="fig"}). Bone mineral density of the lumbar spine (L2--L4) was 0.785 g/cm^2^, which was comparable to that of a 9-yr-old girl. There were no abnormalities found in brain magnetic resonance imaging and fiberscopic investigation of the laryngopharynx. These clinical data prompted us to investigate the causative gene of overgrowth syndrome such as Sotos syndrome and Weaver syndrome. The deletion of the *NSD1* gene, a causative gene of Sotos syndrome, was surveyed by FISH analysis on metaphase spreads prepared from peripheral lymphocytes ([@r9]). The mutation was surveyed by direct sequencing of exons 2--23 covering the whole coding region of *NSD1*, using genomic DNA extracted from peripheral leukocytes ([@r11]). Neither deletion nor a point mutation was found in the *NSD1* gene.

Discussion {#s3}
==========

In this paper, we reported a patient with rare overgrowth disease, Weaver syndrome of which only about forty cases have been reported. The diagnosis of Weaver syndrome was made on the basis of major symptoms: *i.e.*, excessive growth, craniofacial abnormalities, advanced and disharmonic bone age, and mental retardation. Differential diagnosis from Sotos syndrome is most important, because these two syndromes partially overlap. The clinical manifestations of Weaver syndrome and Sotos syndrome are shown in [Table 1](#tbl_001){ref-type="table"}Table 1The clinical manifestations of Weaver syndrome and Sotos syndrome. In Sotos syndrome, despite overgrowth in infancy and childhood, final height is within normal limits for the population in most cases. In contrast, in the case of Weaver syndrome carpal bone age advances compared to phalangeal bone age and final height tends to be excessive.

Kurotaki *et al.* reported haploinsufficiency of the *NSD1* gene on 5q35 in Sotos syndrome ([@r9]). They identified 50 microdeletions (45%) and 16 point mutations (14%) of *NSD1* among 112 patients with Sotos syndrome, and indicated that 77% of individuals had either deletions or point mutations ([@r12]). Douglas *et al.* reported that *NSD1* mutations were found in certain cases of Weaver syndrome ([@r10]). They demonstrated that 28 of 37 (76%) patients with typical Sotos syndrome had mutations or deletions in the *NSD1* gene, and that 3 of 7 (42%) patients with Weaver syndrome had mutations. Recently, Turkman *et al.* identified mutations in the *NSD1* gene in 18 of 20 (90%) patients with Sotos syndrome ([@r13]). In contrast, they found no mutations of the *NSD1* gene in five patients with Weaver syndrome, suggesting that these two syndromes might be different in terms of causative genes. Identification of the *NSD1* gene as the causative gene in Sotos syndrome is a breakthrough for elucidating the mechanism of overgrowth. However, the function of the *NSD1* gene product remains unclear, and certain cases with Sotos syndrome have neither deletion nor mutation of the *NSD1* gene, suggesting that other causes also exist. This report demonstrates that there is at least one patient with Weaver syndrome who has no abnormalities of the *NSD1* gene.

Since the final height in Weaver syndrome is predicted to be excessive, some therapy will be required in the near future to suppress our patient's growth. Voorhover *et al.* reported a girl with Weaver syndrome who reached a final height of 186 cm (\> 97th percentile) and weight of 85 kg ([@r14]). She was treated with high doses of estrogen from the age of 11 to 14.5 yr in order to keep her final height within reasonable limits. Estrogen treatment induces growth plate fusion ([@r15]), thereby reducing the final height, but it might also increase the risk of malignancies of the breast and uterus later in life.

Further investigation of the etiology and pathophysiology of Weaver syndrome is needed to improve management of overgrowth in this syndrome.
